Emergence and dissemination of a highly vancomycin-resistant vanA strain of Enterococcus faecium at a large teaching hospital

J Clin Microbiol. 1997 Jun;35(6):1565-70. doi: 10.1128/jcm.35.6.1565-1570.1997.

Abstract

We prospectively identified patients at the Massachusetts General Hospital from whom vancomycin-resistant enterococci (VRE) were isolated from a clinical specimen from 1 January 1991 through 31 December 1995. VRE strains were available from 139 (82%) of the 169 patients with clinical cases. Of these, 39 (28%) were identical or closely related by pulsed-field gel electrophoresis (i.e., VRE type A strain), including 38 (43%) of 89 VRE strains in 1995. By multivariate analysis, acquisition of the VRE type A strain was associated with receipt of clindamycin (odds ratio [OR] = 10.5), 15 or more days of hospitalization before the first isolation of VRE (OR = 2.9), and residence on one of the general medical floors (OR = 7.8). The VRE type A strain was a vanA strain of Enterococcus faecium and was highly resistant to all antimicrobial agents tested except chloramphenicol. These findings document the rapid dissemination of a highly resistant strain of E. faecium among patients and among other extant VRE strains at the Massachusetts General Hospital in 1995.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Child, Preschool
  • Clindamycin / therapeutic use
  • Cross Infection / epidemiology
  • Cross Infection / microbiology*
  • Disease Outbreaks
  • Drug Resistance, Microbial
  • Enterococcus / drug effects
  • Enterococcus / isolation & purification
  • Enterococcus faecium / drug effects*
  • Enterococcus faecium / isolation & purification
  • Female
  • Gram-Positive Bacterial Infections / epidemiology
  • Gram-Positive Bacterial Infections / microbiology*
  • Hospitals, Teaching
  • Humans
  • Length of Stay
  • Male
  • Massachusetts
  • Middle Aged
  • Prospective Studies
  • Risk Factors
  • Vancomycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Clindamycin
  • Vancomycin